VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that Shawn Singh, VistaGen’s Chief Executive Officer, will present at the 2019 ChinaBio® Partnering Forum held at the Kerry Hotel Pudong in Shanghai, China, on Wednesday, May 8, 2019 at 3:00 p.m. China Standard Time.

For more information regarding the conference, or to schedule a one-on-one meeting with VistaGen’s management team, please contact the Company’s representative in China, Greg Scott, CEO of ChinaBio at Greg.Scott@ChinaBio.com.

About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. VistaGen’s CNS pipeline includes three drug candidates with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety.

For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

Company Contact

Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Media Contact
Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com

SOURCE: VistaGen Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/544439/VistaGen-Therapeutics-to-Present-at-ChinaBioR-Partnering-Forum-in-Shanghai-China

user

Recent Posts

Avant Brands Announces $3.9 Million Private Placement of Unsecured Convertible Debenture Units

KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or…

2 hours ago

The International Myeloma Foundation Mourns the Passing of IMF Board Member and Support Group Leader Jack Aiello

STUDIO CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF)…

2 hours ago

Senti Bio Announces Reverse Stock Split

Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif.,…

2 hours ago

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI…

2 hours ago

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved…

2 hours ago